MCID: PRT030
MIFTS: 45

Parathyroid Gland Disease

Categories: Endocrine diseases

Aliases & Classifications for Parathyroid Gland Disease

MalaCards integrated aliases for Parathyroid Gland Disease:

Name: Parathyroid Gland Disease 12 15
Parathyroid Diseases 44 72
Disease of Parathyroid Glands 12
Parathyroid Disease 17

Classifications:



External Ids:

Disease Ontology 12 DOID:11201
ICD9CM 35 252 252.9
MeSH 44 D010279
NCIt 50 C26844
SNOMED-CT 68 73132005
ICD10 33 E21.4 E21.5
UMLS 72 C0030517

Summaries for Parathyroid Gland Disease

Disease Ontology : 12 An endocrine system disease that is located in the parathyroid gland.

MalaCards based summary : Parathyroid Gland Disease, also known as parathyroid diseases, is related to hyperparathyroidism 1 and paraneoplastic syndromes. An important gene associated with Parathyroid Gland Disease is PTH (Parathyroid Hormone), and among its related pathways/superpathways are G alpha (s) signalling events and Ca, cAMP and Lipid Signaling. The drugs Parathyroid hormone and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, kidney and bone, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 75 Many conditions are associated with disorders of the function of the parathyroid gland. Parathyroid... more...

Related Diseases for Parathyroid Gland Disease

Diseases related to Parathyroid Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 1 30.5 MEN1 CDC73
2 paraneoplastic syndromes 30.5 PTHLH FGF23
3 pseudohypoparathyroidism 30.4 PTHLH PTH BGLAP
4 adenoma 30.4 RET MEN1 CDC73 CASR
5 thyroid gland disease 30.4 RET PTH CALCA
6 multiple endocrine neoplasia 30.4 RET MEN1 CALCA
7 hypoparathyroidism 30.3 TBCE PTHLH PTH GCM2 FGF23 CASR
8 hyperparathyroidism 2 with jaw tumors 30.1 RET MEN1 CDC73 CASR
9 thyroid carcinoma, familial medullary 30.1 RET MEN1 CALCA
10 hypophosphatemia 29.9 PTH FGF23 BGLAP
11 multiple endocrine neoplasia, type iia 29.6 RET PTH MEN1 CDC73 CALCA
12 multiple endocrine neoplasia, type i 29.5 RET PTH MEN1 CDC73 CASR
13 hyperparathyroidism 29.5 VDR RET PTHLH PTH MEN1 GCM2
14 bone resorption disease 29.5 VDR PTH CALCA BGLAP
15 parathyroid carcinoma 29.4 RET PTH MEN1 CDC73 CASR CALCA
16 familial isolated hyperparathyroidism 29.3 RET PTH MEN1 GCM2 CDC73 CASR
17 uremia 29.3 VDR PTH CASR ALB
18 metabolic acidosis 29.2 PTH BGLAP ALB
19 kidney disease 28.4 VDR PTH FGF23 CASR ALB
20 hyperphosphatemia 28.4 VDR PTH KL GCM2 FGF23 CASR
21 bone disease 28.3 VDR PTHLH PTH FGF23 CASR CALCA
22 parathyroid adenoma 27.4 VDR RET PTHLH PTH MEN1 GCM2
23 primary hyperparathyroidism 26.2 VDR RET PTHLH PTH MEN1 GCM2
24 rare genetic parathyroid disease and phosphocalcic metabolism disorder 12.2
25 rare parathyroid disease and phosphocalcic metabolism anomaly 12.2
26 hypocalciuric hypercalcemia, familial, type i 10.7 PTH CASR
27 hypocalciuric hypercalcemia, familial, type ii 10.7 PTH CASR
28 parathyroid transitional clear cell adenoma 10.7 PTH MEN1
29 sclerosing hepatic carcinoma 10.6 PTHLH PTH
30 axial osteomalacia 10.6 PTH BGLAP
31 invasive malignant thymoma 10.6 PTHLH PTH
32 fibrogenesis imperfecta ossium 10.5 PTH CALCA
33 familial hypocalciuric hypercalcemia 10.5 PTH CDC73 CASR
34 pancreatic somatostatinoma 10.5 MEN1 CALCA
35 hypocalciuric hypercalcemia, familial, type iii 10.5 PTHLH PTH CASR
36 clear cell adenoma 10.5 PTHLH PTH MEN1
37 cell type benign neoplasm 10.4 PTH MEN1 CDC73
38 chief cell adenoma 10.4 PTH GCM2
39 hypercalciuria, absorptive, 2 10.4 VDR CASR
40 oncogenic osteomalacia 10.4 PTHLH PTH FGF23
41 extraskeletal chondroma 10.4 PTHLH PTH BGLAP
42 hypoadrenalism 10.4 PTHLH CALCA
43 impaired renal function disease 10.4 PTH FGF23 BGLAP
44 pancreatic cholera 10.4 MEN1 CALCA
45 pseudohypoparathyroidism, type ib 10.3 PTHLH PTH BGLAP
46 cloacogenic carcinoma 10.3 PTHLH PTH CALCA
47 multiple endocrine neoplasia, type iib 10.3 RET MEN1 CALCA
48 hypophosphatasia, adult 10.3 PTH CALCA BGLAP
49 pulmonary alveolar microlithiasis 10.3 PTH FGF23
50 multicentric carpotarsal osteolysis syndrome 10.3 PTHLH BGLAP

Graphical network of the top 20 diseases related to Parathyroid Gland Disease:



Diseases related to Parathyroid Gland Disease

Symptoms & Phenotypes for Parathyroid Gland Disease

MGI Mouse Phenotypes related to Parathyroid Gland Disease:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.33 AIRE ALB CASR CDC73 FGF23 GCM2
2 homeostasis/metabolism MP:0005376 10.29 AIRE ALB CASR CDC73 FGF23 GCM2
3 growth/size/body region MP:0005378 10.28 AIRE CASR CDC73 FGF23 FGF3 KL
4 mortality/aging MP:0010768 10.28 AIRE ALB CASR CDC73 FGF23 FGF3
5 cellular MP:0005384 10.27 ALB CASR CDC73 GCM2 KL MEN1
6 digestive/alimentary MP:0005381 10.26 AIRE ALB CASR CDC73 FGF23 KL
7 behavior/neurological MP:0005386 10.24 AIRE CASR CDC73 FGF3 KL PTHLH
8 immune system MP:0005387 10.24 AIRE CASR CDC73 FGF23 FGF3 KL
9 cardiovascular system MP:0005385 10.19 CDC73 FGF23 KL MEN1 PTH PTHLH
10 hematopoietic system MP:0005397 10.18 AIRE CASR CDC73 FGF23 KL PTH
11 craniofacial MP:0005382 10.11 CDC73 GCM2 KL MEN1 PTH PTHLH
12 limbs/digits/tail MP:0005371 10.02 FGF23 FGF3 KL PTH PTHLH RET
13 nervous system MP:0003631 10.02 AIRE CDC73 FGF3 GCM2 KL MEN1
14 muscle MP:0005369 10.01 ALB CASR CDC73 KL MEN1 RET
15 liver/biliary system MP:0005370 9.93 AIRE ALB CDC73 KL MEN1 PTHLH
16 renal/urinary system MP:0005367 9.91 ALB CASR CDC73 FGF23 GCM2 KL
17 neoplasm MP:0002006 9.85 AIRE ALB CDC73 MEN1 PTHLH RET
18 reproductive system MP:0005389 9.81 AIRE CDC73 FGF23 FGF3 KL MEN1
19 respiratory system MP:0005388 9.5 AIRE CDC73 FGF23 KL PTHLH RET
20 skeleton MP:0005390 9.28 CASR CDC73 FGF23 FGF3 GCM2 KL

Drugs & Therapeutics for Parathyroid Gland Disease

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Cholecalciferol Cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets (or vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia [F4027, F4042]. Concurrently, as one of the most commonly utilized forms of vitamin D, cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin D deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease, among others [A176041, A176044, F4051]. DB00169
2 Ergocalciferol Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.[FDA label] Hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This condition produces decreased calcium and increased phosphorus levels.[L6082] Rickets is a condition produced due to a deficiency in vitamin D, calcium or phosphorus. However, this condition can also be related to renal diseases. It is characterized to present weak or soft bones.[A177664] Familial hypophosphatemia is characterized by the impaired transport of phosphate and an altered vitamin D metabolism in the kidneys. The presence of this condition can derive in the presence of osteomalacia, bone softening and rickets.[L6085] DB00153
3 Parathyroid hormone For use/treatment in osteoporosis. DB05829

Drugs for Parathyroid Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Codeine Approved, Illicit Phase 4 76-57-3 5284371
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6 Peripheral Nervous System Agents Phase 4
7 Central Nervous System Depressants Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Narcotics Phase 4
10 Respiratory System Agents Phase 4
11 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
12 Analgesics Phase 4
13 Analgesics, Opioid Phase 4
14 Antipyretics Phase 4
15 Antitussive Agents Phase 4
16
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
17
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
18
Choline Approved, Nutraceutical Phase 3 62-49-7 305
19
Calcifediol Approved, Nutraceutical Phase 3 19356-17-3 6433735 5283731
20
Calcitriol Approved, Nutraceutical Phase 3 32222-06-3 5280453 134070
21 Technetium Tc 99m Sestamibi Phase 3
22 Vitamins Phase 2, Phase 3
23 Calciferol Phase 2, Phase 3
24 Trace Elements Phase 2, Phase 3
25 Micronutrients Phase 2, Phase 3
26 1 alpha-hydroxyergocalciferol Phase 3
27 Ergocalciferols Phase 3
28 Nutrients Phase 2, Phase 3
29 Vitamin D2 Phase 3
30 Bone Density Conservation Agents Phase 3
31 Gastrointestinal Agents Phase 3
32 Nootropic Agents Phase 3
33 Lipid Regulating Agents Phase 3
34 Hypolipidemic Agents Phase 3
35 Antimetabolites Phase 3
36 Pharmaceutical Solutions Phase 2
37
Cefazolin Approved 25953-19-9 656510 33255
38
Piperacillin Approved 66258-76-2 43672
39
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
40
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
41
Pancrelipase Approved, Investigational 53608-75-6
42
Epinephrine Approved, Vet_approved 51-43-4 5816
43
Racepinephrine Approved 329-65-7 838
44
Oxycodone Approved, Illicit, Investigational 76-42-6 5284603
45
Ibuprofen Approved 15687-27-1 3672
46
Hydrocodone Approved, Illicit, Investigational 125-29-1 5284569
47
Formaldehyde Approved, Vet_approved 50-00-0 712
48
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
49
Biotin Approved, Investigational, Nutraceutical 58-85-5 171548
50 Anti-Infective Agents

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
2 Clinical Value of 18F -Fluorocholine (18F-FCH) PET in Localizing Parathyroid Lesions: Comparison With 99mTc-sestamibi (MIBI) Scan. Completed NCT03555487 Phase 3 18F-choline PET
3 A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism Completed NCT01219855 Phase 2, Phase 3 Cohort 1 CTAP101 Capsules- 60µg;Cohort 1 CTAP101 Capsules - 90µg;Cohort 1 Matching Sugar Capsule;Cohort 2 CTAP101 Capsules - 30µg;Cohort 2 Matching Sugar Capsule
4 A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002) Completed NCT02282813 Phase 3 CTAP101 Capsules;Calcitriol;Doxercalciferol;Paricalcitol
5 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency Completed NCT01704079 Phase 3 CTAP101 30 μg capsules
6 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency Completed NCT01651000 Phase 3 CTAP101 30 μg capsules
7 Prevention of Laryngeal Reflexes in Minimal Invasive Parathyroid Surgery by the Use of Topical Lidocaine Withdrawn NCT00528502 Phase 3 Lidocaine;Saline
8 An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis Completed NCT00742716 Phase 2 CTA018 Injection
9 PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism Recruiting NCT04009291 Phase 2
10 Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis Completed NCT00792857 Phase 1 CTAP201 Injection;Doxercalciferol
11 A Randomized, Open-Label, Single-Dose Pilot Study of Oral and i.v. CTAP101 Evaluating PK and Safety in Stage 3 and 4 CKD Subjects With Vitamin D Insufficiency and SHPT Completed NCT00888069 Phase 1 CTAP101 Capsules;CTAP101 Injection
12 Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders Unknown status NCT00403598
13 Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery Completed NCT01805856 PIPC piperacillin sodium;CEZ, cefazolin sodium
14 Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease Completed NCT01545622
15 Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC Completed NCT01574287 FACBC
16 A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers Completed NCT01794676
17 Complications of Endocrine Surgery: Data From the United Health System Consortium Completed NCT01539499
18 Utility of the Urine Calcium Creatinine Ratio as a Screening Tool for Vitamin D Deficiency in Infants and Toddlers Completed NCT01105689
19 Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing Completed NCT03034707
20 Nausea and Pain Prophylaxis During Thyroid Surgery, a Comparison of Low-Dose and High-Dose Dexamethasone to Placebo Completed NCT00569920 dexamethasone;natriumchloride 0,9%;dexamethasone
21 Burden of Illness and Disease Associated Emergencies in Chronic Hypoparathyroidism Completed NCT03437174
22 Study of the Efficacy and Safety on the Ultrasonic Ablation Treatment for Secondary Hyperthyroidism in Chronic Kidney Disease Patients. Completed NCT01640184 Active vitamin D
23 Phase 1 Study of Electrical Impedance Spectroscopy in Thyroid and Parathyroid Surgery Completed NCT02901873
24 Lower Vitamin D Levels During Second Trimester Are Associated With Developing Gestational Diabetes Mellitus: an Observational Cross-sectional Study Completed NCT03665974
25 Effect of Periodontitis on Bone Mineral Density in Postmenopausal Women Completed NCT02628197
26 Establishment of a Parathyroid Tissue Bank Recruiting NCT03051126
27 Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease Recruiting NCT03050762
28 Are Narcotic Pain Medications Necessary Following Thyroidectomy and Parathyroidectomy Recruiting NCT03640247 Non-narcotic group regimen;Narcotic group regimen
29 Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy Active, not recruiting NCT01539486
30 Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study Active, not recruiting NCT03747029
31 Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients Terminated NCT03044600
32 Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism Terminated NCT00639405

Search NIH Clinical Center for Parathyroid Gland Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cholecalciferol
Ergocalciferol
Parathyroid hormone

Cochrane evidence based reviews: parathyroid diseases

Genetic Tests for Parathyroid Gland Disease

Anatomical Context for Parathyroid Gland Disease

MalaCards organs/tissues related to Parathyroid Gland Disease:

41
Thyroid, Kidney, Bone, Testes, Breast, Adrenal Gland, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Parathyroid Gland Disease:

19
Parathyroid Gland

Publications for Parathyroid Gland Disease

Articles related to Parathyroid Gland Disease:

(show top 50) (show all 126)
# Title Authors PMID Year
1
Parathyroid Diseases. 38
30921001 2019
2
Current concepts in parathyroid carcinoma: a single Centre experience. 38
31142320 2019
3
Management of brown tumor of spine with primary hyperparathyroidism: A case report and literature review. 38
30946329 2019
4
Study of the Ultrasound Appearance of the Normal Parathyroid Using an Intraoperative Procedure. 38
29802631 2019
5
Risk factors and prognosis of voice disorders after surgical treatment of thyroid and parathyroid diseases. 38
31120441 2019
6
[Trends in parathyroid hormone plasma concentration in critically ill patients: prospective observational study]. 38
30796860 2019
7
Metastases to the Parathyroid Glands: A Comprehensive Literature Review of 127 Reported Cases. 38
28875280 2018
8
Usefulness of preoperative ultrasonographic localization for diagnosis of a rare disease: Intrathyroid parathyroid lesions. 38
29879058 2018
9
Metabolic Syndrome in Parathyroid Diseases. 38
29895021 2018
10
Resource utilization associated with cervical hematoma after thyroid and parathyroid surgery. 38
28985879 2017
11
MULTIGLANDULAR PARATHYROID GLAND DISEASE: AN INCIDENTAL DISCOVERY IN NORMOCALCEMIC PATIENTS DURING THYROID SURGERY. 38
31149199 2017
12
Parathyroid Diseases and T Cells. 38
28421466 2017
13
Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. 38
27802177 2017
14
Toxic and Endocrine Myopathies. 38
27922495 2016
15
Sonography of Normal and Abnormal Thyroid and Parathyroid Glands. 38
27002829 2016
16
Sporadic multiple parathyroid gland disease--a consensus report of the European Society of Endocrine Surgeons (ESES). 38
26542689 2015
17
Ultrasensitive Impedimetric Biosensor Fabricated by a New Immobilisation Technique for Parathyroid Hormone. 38
25935225 2015
18
Parathyroid adenoma in patients with Graves' disease: a report of 21 cases. 38
25501495 2015
19
[Efficiency of (99)Tc(m)-sestamibi in diagnosis of parathyroid diseases with primary hyperparathyroidism]. 38
25916532 2015
20
Primary hyperparathyroidism during pregnancy. 38
25367603 2015
21
Hypocalcaemia after total thyroidectomy: could intact parathyroid hormone be a predictive factor for transient postoperative hypocalcemia? 38
25616948 2015
22
Vignette hyperparathyroidism: glimpse into its history. 38
25216416 2014
23
Incidence and risk factors for injuries to the recurrent laryngeal nerve during neck surgery in the moderate-volume setting. 38
24402457 2014
24
Is there a role for video-assisted parathyroidectomy in regions with high prevalence of goitre? 38
24376294 2013
25
[Minimally invasive video-assisted parathyroidectomy (MIVAP) using primary hyperparathyroidism therapy (pHPT)]. 38
24479514 2013
26
Location, number and morphology of parathyroid glands: results from a large anatomical series. 38
22689148 2012
27
Parathyroid diseases and animal models. 38
22754549 2012
28
Diseases of the parathyroid gland in chronic kidney disease. 38
21818548 2011
29
Gastrointestinal motility disorders in endocrine diseases. 38
21532535 2011
30
Overcoming obstacles to setting up office-based ultrasound for evaluation of thyroid and parathyroid diseases. 38
21305549 2011
31
Endocrine problems in pregnancy. 38
21081587 2011
32
The parathyroids and the gut. 38
20485190 2010
33
[Association between thyroid and parathyroid diseases]. 38
20646378 2010
34
Diagnostic pitfalls in parathyroid gland cytology. 38
20432729 2010
35
Validity of dual tracer 99mTc-tetrofosmin and 99mTc-pertechnetate subtraction parathyroid scintigraphy in patients with primary and secondary hyperparathyroidism. 38
20095513 2009
36
[Radio-guided parathyroidectomy]. 38
20109383 2009
37
Cinacalcet in hyperfunctioning parathyroid diseases. 38
19765257 2009
38
2009 EANM parathyroid guidelines. 38
19471928 2009
39
Animal models of hyperfunctioning parathyroid diseases for drug development. 38
23489166 2009
40
Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. 38
19176646 2009
41
Postauricular and axillary approach endoscopic neck surgery: a new technique. 38
19198933 2009
42
Post-operative care through tele-follow up visits in patients undergoing thyroidectomy and parathyroidectomy in a resource-constrained environment. 38
19246606 2009
43
Molecular alterations in hereditary and sporadic thyroid and parathyroid diseases. 38
19098464 2009
44
The additional diagnostic value of a single-session combined scintigraphic and ultrasonographic examination in patients with thyroid and parathyroid diseases. 38
18927523 2008
45
Minimally invasive thyroid and parathyroid surgery is not a question of length of the incision. 38
18716792 2008
46
Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. 9
18436011 2008
47
[Bone metabolism disruption in parathyroid diseases]. 38
18219809 2007
48
Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases. 38
17976083 2007
49
Depression as a manifestation of latent chronic hypoparathyroidism. 38
17366354 2007
50
Mutational analysis of the PTH 3'-untranslated region in parathyroid disorders. 9
17121534 2006

Variations for Parathyroid Gland Disease

Copy number variations for Parathyroid Gland Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160275 22 11800000 24300000 Microdeletion parathyroid gland dysfunction

Expression for Parathyroid Gland Disease

Search GEO for disease gene expression data for Parathyroid Gland Disease.

Pathways for Parathyroid Gland Disease

GO Terms for Parathyroid Gland Disease

Cellular components related to Parathyroid Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 PTHLH PTH KL FGF23 CALCA BGLAP
2 extracellular region GO:0005576 9.56 PTHLH PTH KL FGF3 FGF23 CALCA
3 endoplasmic reticulum lumen GO:0005788 8.92 MEN1 FGF23 BGLAP ALB

Biological processes related to Parathyroid Gland Disease according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.93 VDR PTHLH MEN1 CDC73
2 cell-cell signaling GO:0007267 9.84 PTHLH PTH FGF3 CALCA
3 cellular protein metabolic process GO:0044267 9.8 MEN1 FGF23 CALCA ALB
4 positive regulation of protein kinase B signaling GO:0051897 9.76 RET KL FGF3 FGF23
5 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.75 PTHLH PTH CALCA
6 fibroblast growth factor receptor signaling pathway GO:0008543 9.73 KL FGF3 FGF23
7 skeletal system development GO:0001501 9.71 VDR PTHLH PTH BGLAP
8 decidualization GO:0046697 9.62 VDR MEN1
9 regulation of bone mineralization GO:0030500 9.62 FGF23 BGLAP
10 response to vitamin D GO:0033280 9.61 PTH BGLAP
11 negative regulation of chondrocyte differentiation GO:0032331 9.59 PTHLH PTH
12 vitamin D metabolic process GO:0042359 9.57 VDR FGF23
13 cellular phosphate ion homeostasis GO:0030643 9.55 GCM2 FGF23
14 MAPK cascade GO:0000165 9.55 RET MEN1 KL FGF3 FGF23
15 response to fibroblast growth factor GO:0071774 9.52 PTH CASR
16 phosphate ion homeostasis GO:0055062 9.51 PTH FGF23
17 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.48 KL FGF23
18 bone mineralization GO:0030282 9.43 PTHLH BGLAP
19 osteoblast development GO:0002076 9.43 PTHLH MEN1 BGLAP
20 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.37 VDR FGF23
21 cAMP metabolic process GO:0046058 9.32 PTHLH PTH
22 vasodilation GO:0042311 9.31 CASR
23 response to pain GO:0048265 9.3 RET
24 cellular response to vitamin D GO:0071305 9.13 FGF23 CASR BGLAP
25 cellular calcium ion homeostasis GO:0006874 8.92 VDR PTH GCM2 CASR
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.06 VDR PTH MEN1 GCM2 CDC73 AIRE

Molecular functions related to Parathyroid Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 9.26 PTHLH PTH
2 vitamin D binding GO:0005499 9.16 VDR KL
3 fibroblast growth factor receptor binding GO:0005104 9.13 KL FGF3 FGF23
4 hormone activity GO:0005179 8.92 PTHLH PTH KL CALCA

Sources for Parathyroid Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....